On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV) capsids for gene therapies.
Voyager is a Massachusetts-based company developing AAV-based gene therapies. The
Continue Reading Pfizer and Voyager Agree to Develop Neurologic and Cardiovascular Gene Therapies Valued at up to $630 Million
On September 13, 2021, Regenxbio, a Maryland biotech company, and AbbVie announced that they have entered an agreement to develop and commercialize a potential gene therapy drug developed by Regenxbio for treating age-related macular degeneration (wet AMD), diabetic retinopathy, and
Continue Reading Abbvie and Regenexbio Agree to Develop and Commercialize Eye Disease Gene Therapy
Following the successful development (and financial success) of its mRNA vaccine, biotech company Moderna is now looking to expand into the gene editing field. During a second-quarter earnings call on August 5, 2021, Moderna executives expressed that the company is
Continue Reading Moderna’s Next Steps: Spikevax Today, Gene Editing Tomorrow
Caribou Biosciences, Inc., a Berkeley, California-based CRISPR genome-editing biopharmaceutical company, raised $304M in an initial public offering, one of the most lucrative IPOs in gene-editing. In June 2021, Gene editing biotech Verve raised $267M in IPO proceeds and later added
Continue Reading Caribou Biosciences Raises $304M in Potentially the Largest Gene Editing IPO
On July 15, 2021, American Gene Technologies (AGT), a Maryland biotech company, announced that the safety data in its Phase 1 trial of AGT103-T revealed no adverse effect. Based on the data, the FDA’s Data and Safety Monitoring Board (DSMB)
Continue Reading American Gene Technologies Celebrates Milestone in HIV Cure Development
On July 27, 2021, Amgen announced that it will acquire Bay area-based Teneobio, a privately held, clinical stage biotechnology company developing multispecific and bispecific molecules including biologics called Human Heavy-Chain Antibodies. Under the terms of the agreement, Amgen will
Continue Reading Amgen Acquires Multispecific Immunotherapy Biotech Startup TeneoBio
mRNA pioneer BioNTech announced recently that it is developing an mRNA-based vaccine to attempt to eradicate malaria. Its efforts are geographically focused on Africa, and the company said it is furthering those efforts to build manufacturing capacity on the African
Continue Reading Next Up for BioNTech: Malaria
On July 13, 2021, Prime Medicine, a Massachusetts biotech company developing next generation gene editing technology, emerged from stealth mode with $315 million in financing. The financing includes a $115 million Series A and a $200 million series B investment.
Continue Reading Prime Medicine Emerges with $315 Million to Develop Next Generation Gene Editing Platform
Dual-use ventures—startups that intend to sell both commercially and to the Department of Defense (DoD)—enjoy many advantages. You have a strong opportunity to secure millions of dollars of non-dilutive R&D funding through the SBIR program. With the right product, pitch,
Continue Reading Dual-Use Ventures & Intellectual Property: SBIR Data Rights, Patents, and Deals
In today’s world, e-commerce and online visibility are sine qua non for success. Businesses are willing to invest considerable sums to boost their online presence and maximize sales. Because of this digitalization of business, domain names acquired incredible value. And
Continue Reading Domain Name “Trolls”: The Trademark Trial and Appeal Board May Have Offered A Way Out
